%PDF-1.4
%
56 0 obj
<>
endobj
53 0 obj
<>
endobj
109 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-01-05T11:01:26Z
2024-03-28T03:08:12-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T03:08:12-07:00
application/pdf
Heather
2002-696.feb
uuid:d8a67af3-1dd1-11b2-0a00-f70827edca00
uuid:d8a67af6-1dd1-11b2-0a00-380000000000
endstream
endobj
42 0 obj
<>
endobj
43 0 obj
<>
endobj
57 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 26 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 28 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 30 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 32 0 R/Type/Page>>
endobj
15 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 34 0 R/Type/Page>>
endobj
18 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 36 0 R/Type/Page>>
endobj
131 0 obj
[135 0 R]
endobj
132 0 obj
<>stream
q
0 0 612 792 re
W n
BT
0.8 g
/T1_0 18 Tf
0.6114 0.7912 -0.7912 0.6114 35.383 35.2215 Tm
(Personal, non-commercial use only. The Journal of Rheumatology. Copyrigh\
t \251 2004. All rights reserved.)Tj
ET
Q
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 0.0914 Tw 10 0 0 10 54 713.1616 Tm
(pathogenic role for these antibodies in the development of)Tj
0.03169 Tw 0 -1.21 TD
[(TM. )17.7 (W)79.9 (e would advocate considering longterm anticoagula-)]TJ
-0.0201 Tw T*
(tion in addition to immunosuppressive therapy in these aPL-)Tj
0.0564 Tw T*
(positive patients, although the role of aspirin remains to be)Tj
-0.0002 Tc 0 Tw T*
(clarified.)Tj
/T1_2 1 Tf
-0.00011 Tc 0 -2.4 TD
(REFERENCES)Tj
/T1_1 1 Tf
0.02499 Tw 8 0 0 8 61 630.7617 Tm
[(1.)-875.1 (W)79.9 (est SG. Systemic lupus erythematosus and the nervous system.)]TJ
1.675 -1.25 Td
[(In: )17.7 (W)79.9 (allace DJ, Hahn BH, editors. Dubois\325)-201.1 (lupus erythematosus.)]TJ
0 -1.25 TD
[(6th ed. Philadelphia: Lippincott, )17.7 (W)39.9 (illiams and )17.7 (W)39.9 (ilkins; )]TJ
0 Tc 0 Tw T*
(2002:693-738.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(2.)-875.1 (W)79.9 (est SG. Neuropsychiatric lupus. Rheum Dis Clin North )54.8 (Am)]TJ
0 Tc 0 Tw 1.675 -1.25 Td
(1994;20:29-58.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(3.)-875.1 (Kovacs B, Laf)17.7 (ferty )17.7 (TL, Brent LH, DeHoratius RJ. )17.7 (T)35 (ransverse)]TJ
1.675 -1.25 Td
(myelopathy in systemic lupus erythematosus: an analysis of 14)Tj
T*
[(cases and review of the literature. )54.8 (Ann Rheum Dis 2000;59:120-4.)]TJ
-1.675 -1.25 Td
[(4.)-875.1 (Hochber)17.7 (g MC. Updating the )54.8 (American College of Rheumatology)]TJ
1.675 -1.25 Td
(revised criteria for the classification of systemic lupus )Tj
T*
[(erythematosus [letter]. )54.8 (Arthritis Rheum 1997;40:1725.)]TJ
-1.675 -1.25 Td
[(5.)-875.1 (The )54.8 (American College of Rheumatology nomenclature and case)]TJ
1.675 -1.25 Td
[(definitions for neuropsychiatric lupus syndromes. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1999;42:599-608.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(6.)-875.1 (Barile L, Lavalle C. )17.7 (T)35 (ransverse myelitis in systemic lupus )]TJ
1.675 -1.25 Td
[(erythematosus. )17.7 (The ef)17.7 (fect of IV)-257.3 (pulse methylprednisolone and)]TJ
T*
(cyclophosphamide. J Rheumatol 1992;19:370-2.)Tj
-1.675 -1.25 Td
[(7.)-875.1 (Andrianakos )54.8 (AA, Duf)17.7 (fy J, Suzuki M, Sharp JJ. )17.7 (T)35 (ransverse)]TJ
1.675 -1.25 Td
(myelopathy in systemic lupus erythematosus: report of three cases)Tj
T*
[(and review of the literature. )54.8 (Ann Intern Med 1975;83:616-24.)]TJ
0 Tc -1.675 -1.25 Td
[(8.)-875 (Mok CC, Lau CS, Chan EYT)74 (, )17.7 (W)80 (ong R)54.9 (WS. )54.8 (Acute transverse)]TJ
-0.00011 Tc 1.675 -1.25 Td
(myelopathy in systemic lupus erythematosus: clinical presentation,)Tj
T*
(treatment, and outcome. J Rheumatol 1998;25:467-73.)Tj
31.325 39.221 Td
[(9.)-875.1 (Larsson EM, Holtas S, Cronqvist S. Emer)17.7 (gency magnetic resonance)]TJ
1.675 -1.25 Td
[(examination of patients with spinal cord symptoms. )54.8 (Acta Radiol)]TJ
0 Tc 0 Tw T*
(1988;29:69-75.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(10.)-875.1 (Merine D, )17.7 (W)79.9 (ang H, Kumar )54.8 (AJ, Zinreich SJ, Rosenbaum )54.8 (AE. CT)]TJ
2.175 -1.25 Td
(myelopathy and MRI imaging of acute transverse myelitis. )Tj
T*
[(J Comput )17.8 (T)69.9 (o)-0.1 (mogr 1987;1)36.8 (1:606-8.)]TJ
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Boumpas DT)73.9 (, Patronas NJ, Dalakas MC, Hakim CA, Klippel JH,)]TJ
2.1381 -1.25 Td
[(Balow JE. )54.8 (Acute transverse myelitis in systemic lupus )]TJ
T*
(erythematosus: magnetic resonance imaging and review of the )Tj
T*
(literature. J Rheumatol 1990;17:89-92.)Tj
-2.175 -1.25 Td
[(12.)-875.1 (Lavalle C, Pizarro S, Drenkard C, Sanchez-Guerrero J, )]TJ
2.175 -1.25 Td
[(Alarcon-Segovia D. )17.7 (T)35 (ransverse myelitis: a manifestation of)]TJ
T*
(systemic lupus erythematosus strongly associated with )Tj
T*
(antiphospholipid antibodies. J Rheumatol 1990;17:34-7.)Tj
-2.175 -1.25 Td
[(13.)-875.1 (Bastian HC. )17.7 (Thrombotic softening of the spinal cord. )54.8 (A)-220.1 (case of )]TJ
2.175 -1.25 Td
(so-called \322acute myelitis.\323 Lancet 1910;ii:1531-4.)Tj
-2.175 -1.25 Td
[(14.)-875.1 (Sherer )36.8 (Y)128.9 (, Hassin S, Shoenfeld )36.8 (Y)128.9 (, et al. )17.7 (T)35 (ransverse myelitis in)]TJ
2.175 -1.25 Td
(patients with antiphospholipid antibodies \321 the importance of)Tj
T*
(early diagnosis and treatment. Clin Rheumatol 2002;21:207-10.)Tj
-2.175 -1.25 Td
[(15.)-875.1 (Propper DJ, Bucknall RC. )54.8 (Acute transverse myelopathy )]TJ
2.175 -1.25 Td
[(complicating systemic lupus erythematosus. )54.8 (Ann Rheum Dis)]TJ
0 Tc 0 Tw T*
(1989;48:512-5.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(16.)-875.1 (T)69.9 (ellez-Zenteno JF)79.7 (, Remes-T)34.8 (roche JM, Negrete-Pulido RO, )]TJ
2.175 -1.25 Td
(Davila-Maldonado L. Longitudinal myelitis associated with)Tj
T*
(systemic lupus erythematosus: clinical features and magnetic )Tj
T*
(resonance imaging of six cases. Lupus 2001;10:851-6.)Tj
-2.175 -1.25 Td
[(17.)-875.1 (Lopez Dupla M, Khamashta MA, Sanchez )54.8 (AD, Ingles FP)110.8 (, Uriol PL,)]TJ
2.175 -1.25 Td
[(Aguado )54.8 (AG. )17.7 (T)35 (ranverse myelitis as a first manifestation of systemic)]TJ
T*
(lupus erythematosus: a case report. Lupus 1995;4:239-42.)Tj
-2.175 -1.25 Td
[(18.)-875.1 (Chan KF)79.7 (, Boey ML. )17.7 (T)35 (ransverse myelopathy in SLE: clinical)]TJ
2.175 -1.25 Td
(features and functional outcomes. Lupus 1996;5:294-9.)Tj
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_3 1 Tf
8 0 0 8 54.5 35.9844 Tm
[(D\325Cruz, et al: T)54.8 (ransverse myelitis and SLE)]TJ
0 Tc 0 Tw 61.4375 -0.0313 Td
(285)Tj
ET
0 0 0 0 k
/GS0 gs
109.22 59.09 396.48 -10.84 re
f*
0.5 w
109.22 59.09 396.48 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_4 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_5 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
36 0 obj
<>stream
8;Z\7;6Ih[#itt$j>nr"@0S6iXm:GKKLrW,>(pBM9N;ISIg)77br@>rhf3:]a2h1`
8mAa0=_i6T.#GWMe2P>@\Jd&HY`Zd$.B#YA7l\WLM*a-j3tl4eBNRLaB/
<_V[RVO6u!("Ra",j7SOh43.&^SNM9M3>Rc/VM-p#dq\7uRgHNoO)u$hM"
endstream
endobj
40 0 obj
[/Indexed/DeviceRGB 255 39 0 R]
endobj
39 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
96 0 obj
<>
endobj
62 0 obj
<>
endobj
64 0 obj
<>
endobj
60 0 obj
<>
endobj
83 0 obj
<>
endobj
114 0 obj
<>
endobj
59 0 obj
<>
endobj
76 0 obj
<>stream
HUkPS>'`-ZT
Z""yX @@$ @D"D䪵RhNvtsQ;gYk߬o1s@w|E">Ee~#8,d3sm>ccav.h#C,lUZ:q``;6͟O'qnMk*OO4Ljϻ_FWq9Q TrH"SIeiRYBAӛSRWX9-EkUǴXN
Y|H/;HKATB&7+2Zlɕ rq8^&}cua\gac[䀭pX4dl6XXJ6+ED&Jr#FqF؎ʟlvsv>v#ؾ70}NSo[s/S;IOUͽf>ͣyrV?M0{#ã[J$M*0}BQ-ϔsԹ:nQ^mhfAN'/pw@:ɣS)Yi6wv*RR)]+hkÛ§loOEĮ\ґ{㒣':3W6^kt#&OpL;yڟۓI]F}+ 5lGCjmR`ߵTw;1lvK="4PĪ.Uz:mpMz< ߅L5O.A &L5m=U\4N.HT//ҕizλ-ANĹӲ
Ub37͊"u@U)x{y-#|MaBmPr>uYoatxX6R3o"[U$*#G<$/l#w_ zrd-nw2թxk,TD۸mQa淯Er7C]7yg1UwŤS\k>s-1K-^F)yӗ]c!U+dd)
AFgQq[&:t5>y&i$e'/ld4e/찟7xr_XEVK!?`N;l73f)